+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Proliferatíve Response of T Lymphocytes to Mitogenic Lectins in Essential Hypertension

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Several studies in human and experimental models indicate the existence of a partial relationship between essential hypertension (EH) and the immune system. In this study, cellular immune functions were investigated in 13 patients with untreated and uncomplicated essential hypertension (EHP) and in 10 of their offspring (EHO) and compared to 13 age- and sex-matched normotensive controls (NC) and 10 of their offspring (NCO). The total number of T cells and T cell subsets were similar in all groups examined. In the EHP, basal lymphocyte transformation without lectins was significantly lower (1,126 ± 261 cpm of [<sup>3</sup>H]-thymidine uptake) than in the NC (3,223 ± 736, p < 0.01); the response to both phytohemagglutinin (PHA) and concanavalin A (ConA) revealed reduced [<sup>3</sup>H]-thymidine uptake as compared with NC (21,890 ± 5,432 compared to 64,574 ± 9,723 for PHA and 10,488 ± 2,621 compared to 37,334 ± 8,148 for ConA, respectively, p < 0.01). However, the ability to proliferate as a response to lectins was normal. This was leading to a normal stimulation index in both groups. In the EHO, non-significant decrease in basal transformation and reduced uptake with PHA (49,537 ± 7,478) versus NCO (69,911 ± 7,254) and NC (64,574 ± 9,723) were found. These findings suggest that the proliferative response of T lymphocytes is partially suppressed in EH.

          Related collections

          Author and article information

          S. Karger AG
          11 December 2008
          : 58
          : 4
          : 413-417
          Renal Unit and Eliachar Research Laboratory, Western Galilee Regional Hospital, Nahariya, Israel
          186472 Nephron 1991;58:413–417
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper

          Cardiovascular Medicine, Nephrology

          Lectin, Essential hypertension, Immune functions


          Comment on this article